Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026

VILLEJUIF, France, October 07, 2026–Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a pioneering biotechnology company in the field of next-generation precision therapies (“Valerio”, or the “Company”), provides an update on its operations and presents its financial results for the half-year ended 30 June 2026.Read More